肖碧莲与中国低剂量口服避孕药的研发

摘要

1969年中国通过了1/4剂量口服避孕药的鉴定,进而批量生产和推广使用,是当时世界上临床大量应用的最低剂量.生殖内分泌学家肖碧莲(1923-)是口服避孕药早期研发的重要领导者之一.本文回顾肖碧莲的学术成长经历以及对中国生殖内分泌学的奠基作用,重点梳理其团队的低剂量口服避孕药研发工作,从避孕药的剂量和剂型等变化考察社会经济条件对技术的具体形态的影响,尤其对技术的政治负载加以分析.%In 1969,the low-dose oral contraceptives (1/4 of the conventional dosage) were approved in China.They were mass-produced and used nationwide,which were arguably the lowest dosage widely used in the world.Reproductive endocrinologist,Xiao Bi-Lian (1923-),is an important leader in the early development of oral contraceptives.This article reviews Xiao Bi-Lian's academic growth and her founding role in the establishment of reproductive endocrinology in China,with special focus on her team's endeavor in the development of low-dose oral contraceptives.It examines the shaping power of socio-economic conditions on the specific forms of technology,such as the dosage and formulation of contraceptives.In particular,the relation between technology and politics is analyzed.